Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma

By R. Morgan, Brittney N. Baack, Bryce D. Smith, Anthony K. Yartel, Marc A. Pitasi, Y. Falck-Ytter. Annals of Internal Medicine, 2013

988 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/01a8a88fd0a01bacfd276e1789accfd413921ebb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. A. Jemal
2. R. Siegel
3. K. Miller
4. H. B. EL‐SERAG
5. F. Kanwal
6. Aasld Idsa Hcv Guidance Panel
7. Christoph Sarrazin
8. J. Llovet

In Hepatology

1. J. Llovet
2. V. Mazzaferro
3. Alejandro Forner1 , 2
4. Peter R. Galle
5. H. B. EL‐SERAG
6. A. Jemal
7. F. Piscaglia
8. J. Raoul

Citations in the corpus

• Annual Report to the Nation on the Status of Cancer, 1975–2012, Featuring the Increasing Incidence of Liver Cancer (2016, positive): “Cures of HCV infection are associated with a 75% reduction in the risk of liver cancer.(106,107) In addition to appropriate medical care and management for HCV infection, other strategies to reduce the burden of liver cancer in the United States include promoting hepatitis B vaccination strategies; ”
• Cancer statistics, 2018 (2018, background): “There is potential to avert much of the future burden of liver cancer associated with hepatitis C virus (HCV) infection through increased HCV detection coupled with new, well-tolerated antiviral therapies that lower the risk of hepatocellular carcinoma.(41,42) Most HCV-infected individuals are undia”
• EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. (2018, background): “pression in chronic hepatitis B, decreases, but does not eliminate the risk of HCC.(58,63,107,108) Surveillance should be offered to treated patients with chronic hepatitis B who remain at risk of HCC development because of baseline factors, or those with hepatitis C virus (HCV)-induced advanced fib”
• EASL Recommendations on Treatment of Hepatitis C 2015. (2015, background): “The goal of therapy is to cure HCV infection to prevent hepatic cirrhosis, decompensation of cirrhosis, HCC, severe extra-hepatic manifestations and death (A1) • The endpoint of therapy is undetectable HCV RNA in a sensitive assay (≤15 IU/ml) 12 weeks (SVR12) and 24 weeks (SVR24) after the end of tr”
• Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus (2015, background): “Recent reports suggest that initiating therapy in patients with lower-stage fibrosis may extend the benefits of an SVR.”
• Hepatocellular carcinoma: a review (2016, background): “The risk of HCC is reduced significantly in patients who obtained a sustained viral response after treatment of HCV with a 54% reduction in all-cause mortality.(22) While advances in medications recently have made treating HCV easier, vaccinations against the virus remain elusive.”
• The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer (2016, background): “Moreover, successful eradication of the underlying disease does not completely eliminate the risk for HCC development, as documented in patients with chronic HCV infection (14, 15).”
• Epidemiology of Hepatocellular Carcinoma in the United States: Where Are We? Where Do We Go? (2014, background): “A recent systematic review of observational studies examined the risk of HCC among HCV-infected adults who had been treated and either achieved a sustained virological response (SVR) or did not respond to therapy.(47) SVR was associated with a reduction in RR for HCC for patients at all stages of li”